Skip to Content
Upcoming Webinar

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Date: May 6, 2025 | 2:00 PM

When: Tuesday, May 6 | 2 p.m. EDT
1.0 CE credit is available for eligible participants.

Advancements in CAR T-cell therapy are opening new doors for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). In this Journal Club session, we’ll break down a recent study that’s generating important discussion: Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Led by NCODA Fellow Daisy Doan, PharmD, this session will help you understand how this therapy fits into today’s treatment landscape—and what it means for clinical decision-making.

What to Expect:

  • Describe the current treatment landscape for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including the role of chimeric antigen reception (CAR) T-cell therapies.

  • Investigate the methodology and assumptions used in the “Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia” article.

  • Summarize the key concepts and findings of the “Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia“ article.

  • Relate the significance of “Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia“ to current clinical practice.

To receive ACPE-approved Continuing Education (CE) credit, click here. Registration will open on Monday, May 5th, at 12:00 AM EST.  After registering, please complete the Pre-Test within 10 minutes of the webinar’s start. Credit requirements must be fulfilled within 60 days of the program date. Upon completion, credits will be transmitted electronically to ACPE and reflected in your CPE Monitor profile within 24 hours. 

Login

If you have any questions or would like to request the webinar link, reach out to Jonathan Rivera.